NCT06797622View on ClinicalTrials.gov

Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

February 15, 2025

Primary Completion Date

January 15, 2027

Study Completion Date

April 15, 2027

Conditions

Breast CancerMetastatic Breast Cancer

Interventions

DRUG

Trastuzumab deruxtecan (T-DXd)

Trastuzumab deruxtecan (T-DXd)

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER